Templated high density lipoprotein nanoparticles as potential therapies and for molecular delivery.
暂无分享,去创建一个
C. Shad Thaxton | R. Kannan Mutharasan | R. Mutharasan | C. Thaxton | S. Tripathy | Sushant Tripathy | Marina G. Damiano | Kaylin M. McMahon
[1] R. Hovorka,et al. Effects of intravenous infusion of lipid-free apo A-I in humans. , 1996, Arteriosclerosis, thrombosis, and vascular biology.
[2] J. Gamble,et al. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[3] T. Ishida,et al. Anti-PEG IgM Response against PEGylated Liposomes in Mice and Rats , 2010, Pharmaceutics.
[4] Douglas P. Zipes,et al. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 2-Volume Set, 10th Edition , 2011 .
[5] Aldons J. Lusis,et al. Atherosclerosis : Vascular biology , 2000 .
[6] C. Nelson,et al. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration‐resistant prostate cancer in a mouse xenograft model , 2010, The Prostate.
[7] S. Reddy,et al. Structure and function of HDL mimetics. , 2010, Arteriosclerosis, thrombosis, and vascular biology.
[8] P. Barter,et al. The influence of apolipoproteins on the structure and function of spheroidal, reconstituted high density lipoproteins. , 1994, The Journal of biological chemistry.
[9] E. Schaefer,et al. Metabolic and functional relevance of HDL subspecies , 2011, Current opinion in lipidology.
[10] G. Juliusson,et al. Multilevel regulation of low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in normal and leukemic cells. , 1994, Blood.
[11] N. Kuyucu. Amphotericin B use in children: conventional and lipid-based formulations , 2011, Expert review of anti-infective therapy.
[12] W. Frishman,et al. Apolipoprotein A-I Mimetic Peptides: A Potential New Therapy for the Prevention of Atherosclerosis , 2010, Cardiology in review.
[13] D. Sviridov,et al. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. , 2009, Journal of the American College of Cardiology.
[14] A. Jonas,et al. Lipid transfers between reconstituted high density lipoprotein complexes and low density lipoproteins: effects of plasma protein factors. , 1988, Journal of lipid research.
[15] T. Xia,et al. Toxic Potential of Materials at the Nanolevel , 2006, Science.
[16] K. Pritchard,et al. D-4F, an apoA-1 mimetic, decreases airway hyperresponsiveness, inflammation, and oxidative stress in a murine model of asthma[S] , 2011, Journal of Lipid Research.
[17] A. Folsom,et al. High-density lipoprotein cholesterol and venous thromboembolism in the Longitudinal Investigation of Thromboembolism Etiology (LITE). , 2008, Blood.
[18] D. Rader. Molecular regulation of HDL metabolism and function: implications for novel therapies. , 2006, The Journal of clinical investigation.
[19] S. Kaul,et al. High-Dose Recombinant Apolipoprotein A-IMilano Mobilizes Tissue Cholesterol and Rapidly Reduces Plaque Lipid and Macrophage Content in Apolipoprotein E-Deficient Mice: Potential Implications for Acute Plaque Stabilization , 2001, Circulation.
[20] Nicola J. Armstrong,et al. Haemolysis during Sample Preparation Alters microRNA Content of Plasma , 2011, PloS one.
[21] G. Jenster,et al. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. , 2010, Cancer research.
[22] Chad A. Mirkin,et al. Gene regulation with polyvalent siRNA-nanoparticle conjugates. , 2009, Journal of the American Chemical Society.
[23] M. Oda,et al. Reconstituted high density lipoprotein enriched with the polyene antibiotic amphotericin B Published, JLR Papers in Press, November 28, 2005. , 2006, Journal of Lipid Research.
[24] Paul Schoenhagen,et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. , 2003, JAMA.
[25] A. Kontush,et al. Antiatherogenic small, dense HDL—guardian angel of the arterial wall? , 2006, Nature Clinical Practice Cardiovascular Medicine.
[26] D. Sviridov,et al. Infusion of Reconstituted High-Density Lipoprotein Leads to Acute Changes in Human Atherosclerotic Plaque , 2008, Circulation research.
[27] A. Jonas. Reconstitution of high-density lipoproteins. , 1986, Methods in enzymology.
[28] A. Jonas,et al. CHAPTER 17 – Lipoprotein structure , 2008 .
[29] Thanh-Son Nguyen,et al. All-trans-retinoic acid nanodisks. , 2007, International journal of pharmaceutics.
[30] M. Tallman,et al. Treatment of Acute Promyelocytic Leukemia without Cytotoxic Treatment of Acute Promyelocytic Leukemia without Cytotoxic Chemotherapy Evolution of Induction Therapy in Apl , 2022 .
[31] L. Gordon,et al. Curcumin nanodisk-induced apoptosis in mantle cell lymphoma , 2011, Leukemia & lymphoma.
[32] Chad A Mirkin,et al. Transfection of pancreatic islets using polyvalent DNA-functionalized gold nanoparticles. , 2010, Surgery.
[33] L. Curtiss,et al. Apolipoprotein A-I structural organization in high density lipoproteins isolated from human plasma , 2010, Nature Structural &Molecular Biology.
[34] K. Tsuchida,et al. High-density lipoproteins protect endothelial cells from tumor necrosis factor-alpha-induced apoptosis. , 2000, Biochemical and biophysical research communications.
[35] C. McArdle,et al. Low-density lipoprotein metabolism in mice with soft tissue tumours. , 1984, Biochimica et biophysica acta.
[36] Chad A Mirkin,et al. Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery. , 2011, Nano letters.
[37] L. Cupples,et al. High-Density Lipoprotein Subpopulation Profile and Coronary Heart Disease Prevalence in Male Participants of the Framingham Offspring Study , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[38] Eric Pridgen,et al. Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.
[39] L. Gordon,et al. Curcumin nanodisks: formulation and characterization. , 2011, Nanomedicine : nanotechnology, biology, and medicine.
[40] A. Lacko,et al. Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier , 2009, Journal of drug targeting.
[41] W. Davidson,et al. The Spatial Organization of Apolipoprotein A-I on the Edge of Discoidal High Density Lipoprotein Particles , 2003, Journal of Biological Chemistry.
[42] Robert Langer,et al. Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.
[43] A. Nègre-Salvayre,et al. HDL and ApoA prevent cell death of endothelial cells induced by oxidized LDL. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[44] L. Gordon,et al. All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma , 2010, British journal of haematology.
[45] R. Mahley,et al. DECREASED HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVELS WITH SIGNIFICANT LIPOPROTEIN MODIFICATIONS AND WITHOUT CLINICAL ATHEROSCLEROSIS IN AN ITALIAN FAMILY , 1980 .
[46] W. Gross,et al. Distribution spectrum of paraoxonase activity in HDL fractions. , 2004, Clinical chemistry.
[47] Zahi A Fayad,et al. Properties of a versatile nanoparticle platform contrast agent to image and characterize atherosclerotic plaques by magnetic resonance imaging. , 2006, Nano letters.
[48] C. Schmidt,et al. Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine. , 1985, The Journal of biological chemistry.
[49] E. Morrison,et al. The Role of High-Density Lipoproteins in Reducing the Risk of Vascular Diseases, Neurogenerative Disorders, and Cancer , 2010, Cholesterol.
[50] D. Mozaffarian,et al. Heart disease and stroke statistics--2010 update: a report from the American Heart Association. , 2010, Circulation.
[51] D. Rader,et al. High-Density Lipoprotein Promotes Endothelial Cell Migration and Reendothelialization via Scavenger Receptor-B Type I , 2005, Circulation research.
[52] M. Caulfield,et al. Effects of torcetrapib in patients at high risk for coronary events , 2008 .
[53] Jayanth Panyam,et al. Rapid endo‐lysosomal escape of poly(DL‐lactide‐coglycolide) nanoparticles: implications for drug and gene delivery , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[54] M. Manoharan,et al. Modulation of plasma protein binding and in vivo liver cell uptake of phosphorothioate oligodeoxynucleotides by cholesterol conjugation. , 2000, Nucleic acids research.
[55] Anthony E. Klon,et al. A Detailed Molecular Belt Model for Apolipoprotein A-I in Discoidal High Density Lipoprotein* , 1999, The Journal of Biological Chemistry.
[56] Colin Berry,et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. , 2007, JAMA.
[57] R. Hegele,et al. Is raising HDL a futile strategy for atheroprotection? , 2008, Nature Reviews Drug Discovery.
[58] A. von Eckardstein,et al. HDL and arteriosclerosis: beyond reverse cholesterol transport. , 2002, Atherosclerosis.
[59] B. Hansel,et al. Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia , 2005, Diabetologia.
[60] A. Tall,et al. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[61] Mark E. Davis. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. , 2009, Molecular pharmaceutics.
[62] B. Williams,et al. Efficient suppression of secretory clusterin levels by polymersiRNA polymersiRNA polymersiRNA nanocomplexes enhances ionizing radiation lethality in human MCF7 MCF7 MCF7 breast cancer cells in vitro * , 2006 .
[63] M. Ritter,et al. Role of apolipoprotein A-I in the structure of human serum high density lipoproteins. Reconstitution studies. , 1977, The Journal of biological chemistry.
[64] L. Lim,et al. " off-target " transcript silencing Position-specific chemical modification of siRNAs reduces , 2006 .
[65] Erling Falk,et al. Pathogenesis of atherosclerosis. , 2006, Journal of the American College of Cardiology.
[66] Michael S. Goldberg,et al. Development of lipidoid-siRNA formulations for systemic delivery to the liver. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[67] P. Wilson,et al. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. , 1988, Arteriosclerosis.
[68] J. Benoit,et al. The importance of endo-lysosomal escape with lipid nanocapsules for drug subcellular bioavailability. , 2010, Biomaterials.
[69] Miss A.O. Penney. (b) , 1974, The New Yale Book of Quotations.
[70] D. Sviridov,et al. Reconstituted HDL: a therapy for atherosclerosis and beyond , 2009 .
[71] R. Griffey,et al. Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. , 2005, Journal of medicinal chemistry.
[72] V. Tugnoli,et al. Cholesteryl esters in malignancy. , 2005, Clinica chimica acta; international journal of clinical chemistry.
[73] C. E. West,et al. Separation of plasma lipoproteins by density-gradient ultracentrifugation. , 1975, Analytical biochemistry.
[74] Zahi A Fayad,et al. Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. , 2004, Journal of the American Chemical Society.
[75] G. Assmann,et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. , 2004, The Journal of clinical investigation.
[76] J. Glomset,et al. The plasma lecithins:cholesterol acyltransferase reaction. , 1968, Journal of lipid research.
[77] Minghan Wang,et al. HDL: The Metabolism, Function, and Therapeutic Importance , 2004 .
[78] A. Miyauchi,et al. Evidence for a potential role for HDL as an important source of cholesterol in human adrenocortical tumors via the CLA-1 pathway. , 1999, Endocrine journal.
[79] I. Gelissen,et al. ABCA1 and ABCG1 Synergize to Mediate Cholesterol Export to ApoA-I , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[80] Claudia Calcagno,et al. Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform. , 2008, Nano letters.
[81] Richard G. W. Anderson,et al. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase , 2001, Nature Medicine.
[82] Y. Jo,et al. Differential Regulation of Steroid Hormone Biosynthesis in R2C and MA-10 Leydig Tumor Cells: Role of SR-B1-Mediated Selective Cholesteryl Ester Transport1 , 2003, Biology of reproduction.
[83] M. Stoffel,et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs , 2007, Nature Biotechnology.
[84] M. Siperstein. Role of cholesterogenesis and isoprenoid synthesis in DNA replication and cell growth. , 1984, Journal of lipid research.
[85] William Weintraub,et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. , 2011, The New England journal of medicine.
[86] Khaled Greish,et al. Enhanced permeability and retention of macromolecular drugs in solid tumors: A royal gate for targeted anticancer nanomedicines , 2007, Journal of drug targeting.
[87] D. Rader,et al. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis This work was supported by P01-HL22633 from the NHLBI. Published, JLR Papers in Press, December 8, 2008. , 2009, Journal of Lipid Research.
[88] Matthias John,et al. Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. , 2004, Bioorganic & medicinal chemistry letters.
[89] R. Ryan. Nanodisks: hydrophobic drug delivery vehicles , 2008, Expert opinion on drug delivery.
[90] Honglin Jin,et al. Efficient cytosolic delivery of siRNA using HDL-mimicking nanoparticles. , 2011, Small.
[91] J. Segrest,et al. Studies of synthetic peptide analogs of the amphipathic helix. Correlation of structure with function. , 1985, The Journal of biological chemistry.
[92] C. Mirkin,et al. Nanotechnology for synthetic high-density lipoproteins. , 2010, Trends in molecular medicine.
[93] Kyung-Hyun Cho,et al. A reconstituted HDL containing V156K or R173C apoA-I exhibited anti-inflammatory activity in apo-E deficient mice and showed resistance to myeloperoxidase-mediated oxidation , 2009, Experimental & Molecular Medicine.
[94] Chad A Mirkin,et al. Scavenger receptors mediate cellular uptake of polyvalent oligonucleotide-functionalized gold nanoparticles. , 2010, Bioconjugate chemistry.
[95] Philippe Giral,et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. , 2004, The Journal of clinical endocrinology and metabolism.
[96] Mark E. Davis,et al. Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.
[97] A. Tall,et al. High Density Lipoprotein (HDL) Particle Uptake Mediated by Scavenger Receptor Class B Type 1 Results in Selective Sorting of HDL Cholesterol from Protein and Polarized Cholesterol Secretion* , 2001, The Journal of Biological Chemistry.
[98] B. Karten,et al. The human breast carcinoma cell line HBL-100 acquires exogenous cholesterol from high-density lipoprotein via CLA-1 (CD-36 and LIMPII analogous 1)-mediated selective cholesteryl ester uptake. , 2000, The Biochemical journal.
[99] M. Brown,et al. Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. , 1978, Blood.
[100] H. Maeda,et al. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.
[101] Jianwen Fang,et al. Structure of apolipoprotein A-I in spherical high density lipoproteins of different sizes , 2008, Proceedings of the National Academy of Sciences.
[102] C. Mirkin,et al. Templated spherical high density lipoprotein nanoparticles. , 2009, Journal of the American Chemical Society.
[103] C. Fielding,et al. Molecular physiology of reverse cholesterol transport. , 1995, Journal of lipid research.
[104] Qingming Luo,et al. Biomimetic nanocarrier for direct cytosolic drug delivery. , 2009, Angewandte Chemie.
[105] Subramaniam Pennathur,et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. , 2007, The Journal of clinical investigation.
[106] F. Maxfield,et al. Role of cholesterol and lipid organization in disease , 2005, Nature.
[107] J. Albers,et al. Distribution of high density lipoprotein particles with different apoprotein composition: particles with A-I and A-II and particles with A-I but no A-II. , 1982, Journal of lipid research.
[108] L. Ellis,et al. Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. , 2011, Neoplasia.
[109] P. Barter,et al. The Influence of Cholesteryl Ester Transfer Protein on the Composition, Size, and Structure of Spherical, Reconstituted High Density Lipoproteins (*) , 1995, The Journal of Biological Chemistry.
[110] Helen H. Hobbs,et al. Identification of Scavenger Receptor SR-BI as a High Density Lipoprotein Receptor , 1996, Science.
[111] A. Khera,et al. Future Therapeutic Directions in Reverse Cholesterol Transport , 2010, Current atherosclerosis reports.
[112] J. Sikorski. 6.20 – Atherosclerosis/Lipoprotein/Cholesterol Metabolism , 2007 .
[113] J. Breslow,et al. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[114] Qingming Luo,et al. HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. , 2010, Small.
[115] Mark E. Davis,et al. PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. , 2004, European journal of cell biology.
[116] R. Lallone,et al. Oral Administration of an Apo A-I Mimetic Peptide Synthesized From D-Amino Acids Dramatically Reduces Atherosclerosis in Mice Independent of Plasma Cholesterol , 2002, Circulation.
[117] A. Jonas,et al. Micellar complexes of human apolipoprotein A-I with phosphatidylcholines and cholesterol prepared from cholate-lipid dispersions. , 1982, The Journal of biological chemistry.
[118] A. Kontush,et al. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities , 2010, Current opinion in lipidology.
[119] Serkalem Demissie,et al. Value of High-Density Lipoprotein (HDL) Subpopulations in Predicting Recurrent Cardiovascular Events in the Veterans Affairs HDL Intervention Trial , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[120] A. Rigotti,et al. Cellular and physiological roles of SR-BI, a lipoprotein receptor which mediates selective lipid uptake. , 2000, Biochimica et biophysica acta.
[121] Matthias John,et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs , 2004, Nature.
[122] P. Libby,et al. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 2-Volume Set, 9th Edition Expert Consult Premium Edition €“ Enhanced Online Features , 2011 .
[123] Zahi A Fayad,et al. The biological properties of iron oxide core high-density lipoprotein in experimental atherosclerosis. , 2011, Biomaterials.
[124] Z. Fayad,et al. An ApoA-I mimetic peptide high-density-lipoprotein-based MRI contrast agent for atherosclerotic plaque composition detection. , 2008, Small.
[125] K. Vickers,et al. MicroRNAs are Transported in Plasma and Delivered to Recipient Cells by High-Density Lipoproteins , 2011, Nature Cell Biology.
[126] Linda Mooberry,et al. Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel , 2008, Anti-cancer drugs.
[127] Aalt Bast,et al. Comprehensive medicinal chemistry , 1991 .
[128] Z. Fayad,et al. Comparison of synthetic high density lipoprotein (HDL) contrast agents for MR imaging of atherosclerosis. , 2009, Bioconjugate chemistry.
[129] D. Rader,et al. Laboratory assessment of HDL heterogeneity and function. , 2008, Clinical chemistry.
[130] Heng Zhang,et al. Tailoring of biomimetic high-density lipoprotein nanostructures changes cholesterol binding and efflux. , 2012, ACS nano.
[131] T. Ishida,et al. Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[132] A. Tall,et al. Specific Binding of ApoA-I, Enhanced Cholesterol Efflux, and Altered Plasma Membrane Morphology in Cells Expressing ABC1* , 2000, The Journal of Biological Chemistry.